Regnum CorpOver The Counter Market:RGMP
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regnum Corp | 20.0 | 0.0x | --- |
Evolutionary Genomics Inc | 5.3K | 0.0x | --- |
PZ Wind Down Inc | 10.0 | 0.0x | --- |
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Rebus Holdings Inc | 30.0 | 0.0x | --- |
Poniard Pharmaceuticals Inc | 150.0 | 0.0x | --- |
Company Information
Regnum Corp. is focused on developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges due to inconvenient dosing or delivery system, tolerability, or cost and accessibility of available therapeutic options. The Company's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. Leronlimab is a monoclonal antibody. The target of leronlimab is the immunologic receptor CCR5. Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells. The leronlimab antibody belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. Leronlimab blocks HIV from entering a cell by binding to a molecule called CCR5 referred to as R5 strains, attach as part of HIVs entry into a cell.
Contact Information
- Headquarters
- 600 THIRD AVENUE, 10THNEW YORK, NY, United States 10016
- Phone
- 917-647-1498
- Fax
- ---
Executives
- Chief Financial Officer, Treasurer
- Robert Stubblefield
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $20.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 23.0M |
Regnum Corp does not pay a dividend. | |
Beta | 3.27 |
EPS | $-0.03 |
Book Value | $-0.05 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
